Lonza to Acquire InterHealth for as Much as $300 Million

  • Nutritional ingredient maker to be bought from Kainos Capital
  • Lonza sees immediate boost to earnings from acquisition
Lock
This article is for subscribers only.

Lonza Group AG agreed to buy InterHealth Nutraceuticals for as much as $300 million, a sign the Swiss chemical maker may be back on the hunt for major acquisitions after a break of almost five years.

The purchase of the nutritional ingredients company from private equity firm Kainos Capital is expected to give an immediate boost to earnings, Basel-based Lonza said in a statement on Monday. The drug-ingredient maker is paying about 10 times InterHealth’s earnings before interest, taxes, depreciation and amortization, it said.